Expands Global Footprint with Strategic Partnership in India
Filed with ASX · · 3 pages · English
Earlier from Renerve
- Response to ASX Aware Letter
- Clinical Outcome Demonstrates Material Benefits for Patients
- 1HFY25 Results Announcement
- 1HFY25 Appendix 4D and Half Year Report
- ReNerve - Q2 FY25 Activities Report & Appendix 4C
Later from Renerve
- ReNerve - Q3 FY25 Activities Report & Appendix 4C
- ReNerve receives market approval in Bahrain
- Expands Product Portfolio with Berkley partnership / Webinar
- Q4 FY25 Activities Report and Appendix 4C
- ReNerve records first sale of deep dermal product range
Follow Renerve into a list and get an email when it puts out news.
Follow Renerve